|
|
Article: TransTech RAGE Modulators Subject Of $173M Pfizer Deal.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In its largest deal to date, TransTech Pharma Inc. out-licensed to Pfizer Inc. its portfolio of compounds targeting the receptor for advanced glycation endproducts (RAGE), which includes a Phase II-stage small molecule against Alzheimer's disease and diabetic nephropathy.
In exchange for exclusive, worldwide rights to the RAGE technology, New York-based Pfizer agreed to pay TransTech up to $155 million in up-front and near-term milestone payments, as well as up to $18 million in research funding to support expansion of the portfolio. Beyond that, TransTech said it could receive "significant" milestones for the development and ...